

Resource Summary Report

Generated by [dkNET](#) on Sep 1, 2026

MOLP-8

RRID:CVCL_2124

Type: Cell Line

Proper Citation

RRID:CVCL_2124

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2124

Proper Citation: RRID:CVCL_2124

Description: Cell line MOLP-8 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Plasma cell myeloma

Defining Citation: [PMID:15203285](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30285677](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:32123307](#), [PMID:35839778](#)

Comments: Characteristics: Produces IgD lambda., Population: Japanese., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MOLP-8

Synonyms: MOLP8

Cross References: CLO:CLO_0009849, EFO:EFO_0006654, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioSample:SAMN03472939, BioSample:SAMN10989574, cancercellines:CVCL_2124, Cell_Model_Passport:SIDM00434, CLS:304082, Cosmic-CLP:1330950, DepMap:ACH-000745, DSMZ:ACC-569, DSMZCellDive:ACC-569, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1330950, GEO:GSM562816, GEO:GSM887333, GEO:GSM888409, GEO:GSM1374691, GEO:GSM1670125, IARC_TP53:30124,

LiGeA:CCLE_271, LINCS_LDP:LCL-2047, PharmacDB:MOLP8_954_2019, PRIDE:PXD030304, Progenetix:CVCL_2124, Wikidata:Q54906340

ID: CVCL_2124

Record Creation Time: 20220427T220817+0000

Record Last Update: 20260829T234650+0000

Ratings and Alerts

No rating or validation information has been found for MOLP-8.

No alerts have been found for MOLP-8.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Tang A, et al. (2026) Targeting BCMA in multiple myeloma with a trifunctional NK cell engager. Cell reports. Medicine, 7(3), 102628.

Tiwari PK, et al. (2026) An orally active dual CBP/p300 degrader targets core dependencies of multiple myeloma. Cell reports, 45(6), 117464.

Krishnamoorthy M, et al. (2025) Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy. Frontiers in immunology, 16, 1518787.

Nardone C, et al. (2025) Structural basis for the midnolin-proteasome pathway and its role in suppressing myeloma. Molecular cell, 85(13), 2597.

Shearer T, et al. (2024) Kinetics of Nirogacestat-Mediated Increases in B-cell Maturation Antigen on Plasma Cells Inform Therapeutic Combinations in Multiple Myeloma. Cancer research communications, 4(12), 3114.

Singh RK, et al. (2024) Novel Anti-B-cell Maturation Antigen Alpha-Amanitin Antibody-drug Conjugate HDP-101 Shows Superior Activity to Belantamab Mafodotin and Enhanced Efficacy in Deletion 17p Myeloma Models. Research square.

Barton BE, et al. (2024) Preclinical Evaluation of a Novel Series of Polyfluorinated Thalidomide Analogs in Drug-Resistant Multiple Myeloma. Biomolecules, 14(6).

Maneix L, et al. (2022) Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 (HDAC3) Stabilization and Chromatin

Condensation. Cancer research communications, 2(12), 1693.

Vannam R, et al. (2021) Targeted degradation of the enhancer lysine acetyltransferases CBP and p300. Cell chemical biology, 28(4), 503.

Wells AC, et al. (2017) Modulation of let-7 miRNAs controls the differentiation of effector CD8 T cells. eLife, 6.